Artiva Biotherapeutics announces safety, translational data from AlloNK

Artiva Biotherapeutics (ARTV) announced positive initial safety and translational data from ongoing clinical trials of AlloNK in combination with rituximab or obinutuzumab for the treatment of autoimmune disease. The findings highlight that AlloNK, an allogeneic, non-genetically modified, cryopreserved, off-the-shelf natural killer cell therapy, was generally well tolerated and demonstrated deep B-cell depletion in outpatient and community settings. Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration regulatory interactions to align on pivotal trial design for AlloNK in refractory rheumatoid arthritis in the first half of 2026